Valuation: Interpace Biosciences, Inc.

Market Cap 29.37M 26.16M 24.25M 21.96M 41.31M 2.78B 41.9M 290M 114M 1.46B 110M 108M 4.65B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 28.05M 24.98M 23.16M 20.98M 39.45M 2.66B 40.01M 277M 109M 1.39B 105M 103M 4.44B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+6.00%
1 week-13.54%
Current month-17.06%
1 month-17.83%
3 months-30.49%
6 months-50.35%
Current year-13.84%
1 week 5
Extreme 5
5.82
1 month 5
Extreme 5
6.55
Current year 5
Extreme 5
12
1 year 4.03
Extreme 4.0275
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
48.5
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 Free

Director

69,252 0.2501%
8/20/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
8/20/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+6.00%-13.54%+13.97%+3.92% 27.71M
+2.23%+7.99%+14.82%+34.19% 119B
+2.39%+1.56%+9.29%+90.84% 98.48B
+1.63%+2.05%+123.41%+879.77% 57.57B
-0.38%+4.43%-5.74%+80.34% 28.37B
+0.94%+1.93%+25.12%+93.05% 25.93B
+1.35%+2.41%+13.01%+62.03% 25.86B
+2.23%+1.32%+36.16%+382.58% 21.45B
-0.41%-3.19%-21.76%-5.09% 20.45B
+1.71%-3.63%+8.09%+90.87% 18.69B
Average +1.64%-1.09%+21.64%+171.25% 41.54B
Weighted average by Cap. +1.54%+1.51%+26.69%+191.99%

Financials

2024 2025
Net sales 46.93M 41.79M 38.75M 35.09M 66M 4.45B 66.93M 464M 182M 2.33B 176M 172M 7.43B 38.73M 34.49M 31.98M 28.96M 54.47M 3.67B 55.24M 383M 150M 1.92B 145M 142M 6.13B
Net income 6.7M 5.97M 5.53M 5.01M 9.43M 635M 9.56M 66.22M 26.02M 332M 25.14M 24.62M 1.06B 24.58M 21.89M 20.29M 18.38M 34.56M 2.33B 35.05M 243M 95.42M 1.22B 92.18M 90.26M 3.89B
Net Debt 4.4M 3.91M 3.63M 3.29M 6.18M 417M 6.27M 43.42M 17.07M 218M 16.48M 16.14M 696M -1.32M -1.18M -1.09M -989K -1.86M -125M -1.89M -13.06M -5.13M -65.56M -4.96M -4.86M -209M
Projected Income Statement - Annual - Interpace Biosciences, Inc.
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-10-20 $5.300 +6.00% 1,255
26-10-19 $5.000 -2.91% 7,128
26-10-16 $5.150 -2.28% 1,752
26-10-15 $5.270 -4.49% 3,267
26-10-14 $5.518 -6.47% 261

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Interpace Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. IDXG Stock